The most common deficiency allele of the plasma protease inhibitor a1-antitrypsin (alAT) is PI*Z. Some rare deficiency alleles of alAT produce low but detectable amounts of plasma alAT (1-20% of normal), which can be differentiated by isoelectric focusing. Others, designated null (QO) alleles, produce no alAT detectable by routine quantitative methods. We have previously described a method using DNA polymorphisms, haplotypes, and polyacrylamide isoelectric focusing gels, to differentiate various deficiency alleles. Based on haplotypes, we previously identified, in eight patients, five different null alleles, four of which had been previously sequenced.
Introduction
al-antitrypsin (alAT),' a 52-kD plasma glycoprotein, is the primary inhibitor of the serine protease leukocyte elastase (1) . a lAT is synthesized primarily in the liver, is secreted into the blood, and diffuses into the interstitial fluids (for reviews, see references 2 and 3). a I AT is a highly polymorphic protein with more than 60 electrophoretic variants (4, 5) . A deficiency of a lAT is associated with emphysema and with childhood liver disease (6, 7) . The most common deficiency allele of a lAT is PI*Z, occurring at a frequency of 0.012 in caucasians (8) . The Z allele is associated with a low plasma concentration, less than 20% of normal (8) , and with liver inclusions (9) apparently due to the tendency to aggregate in vitro (10) .
Alleles associated with the most pronounced deficiency states, in which no serum a lAT is detected by routine methods, are designated as null (QO) alleles. The null alleles are rare, with a combined frequency estimated to be loamong caucasians (1 1) . With the goal of delineating the spectrum of mutations that lead to a 1 AT deficiency, we examined DNA from eight individuals with null alleles. By haplotype analysis, following the algorithm of Cox and Billingsley (1 1), we identified a unique null allele, designated QOludwigshafen in an individual of German ancestry. The QOludwigshafen gene was cloned, and sequenced using asymmetric polymerase chain reaction (PCR) amplification. The limitation of the haplotype approach of screening for unique null alleles is that different null mutations may have occurred on the same haplotype background. Therefore, allele-specific oligonucleotide probes were used to further distinguish between different null alleles.
Methods
Protein Studies. Serum a 1 AT was quantified using electroimmuno assay (5, 12) . All sera were examined by isoelectric focusing using narrow range ampholine, Pharmalyne pH 4.2-4.9 (LKB, Sweden), followed by immunoprinting (5, 13) . By these assays, in combination with family studies or haplotype analysis, eight individuals were identified previously as having a null allele (1 1).
Haplotype analysis. These individuals were classified using the algorithm for limited haplotype analysis as described (1 1) . The restriction enzymes used to determine the polymorphic sites forming the haplotypes are listed in Table I in an order that represents the location ofthe polymorphic sites of the a I AT gene and the related PI-like (PIL) gene. Probes used, designated 6.5 (pAT 6.5) and 4.6 (pAT 4.6) ( Fig. 1 ), were provided by S. L. C. Woo. The last five restriction sites listed, not contained within the 6.5 probe, represent polymorphisms in the PIL gene (unpublished data), located 8 to 12 kb downstream of the alAT gene (16, 17) . The previous identification of the unique PI*Z haplotype in 55 of 58 individuals examined (14) allowed the assignment of the complete QOludwigshafen (QOlud) haplotype in the proband, a QOludZ compound heterozygote. The QOludwigshafen allele was initially identified as a unique null allele based on its haplotype. Gene cloning. High molecular weight DNA suitable for cosmid cloning was extracted from leukocytes from the proband (18) . DNA was partially digested with Mbo I, fractionated by sucrose density gradient centrifugation (19) and fractions containing 23 to 50 kb DNA fragments were ligated to the double cos site vector, C2RB (20) . Clones were screened (21) with an exon I-specific probe ( Fig. 1 ). Positive clones were digested with Eco RI to determine the integrity of the full-length genes. QOludwigshafen clones were distinguished from Z clones by two restriction site differences using either Msp I with probe 4.6 or a double digest using Bst EII and Pst I with probe 6.5. Locations of the two polymorphic sites are indicated ( Fig. 1 ). Sequencing. Cosmid DNA containing the full-length gene was prepared from one QOludwigshafen clone (22) . Single-stranded DNA was prepared for each of the coding exons (II through V) by asymmetric PCR amplification as used on genomic DNA (23), except that 15-150 pg of cosmid DNA was amplified. 11 synthetic primers were used and 7 regions were amplified ( Fig. 1 ). Amplification primers were as fol- (11, 14, 15) . t The QOludwigshafen (QOlud) haplotype was initially deduced from the assignment of the proband's Z haplotype, based upon the previous identification of a unique Z haplotype in 55 of 58 individuals examined (53) .
lows: exon 11, 5' GGTGTCAATCCCTGATCACT, 3' TTGCCAAGG-AGAGTTCAAGA; exon III, 5' TTCTGCTACACTCTTCCAAA, 3' AGTCCCAACATGGCTAAGAG; exon IV, 5' GTCCCAGAAGAA-CAAGAGGA, 3' CACATTCTTCCCTACAGATA; exon V, 5' TCA-GCCTTACAACGTGTCTC, 3' CAGAGAAAACATCCCAGGGA. Exon IV sequence was confirmed by priming from a site within exon V resulting in a 1.3-kb single-stranded template ( Fig. 1 ). DNA was concentrated and unincorporated nucleotides were removed with a Centricon-30 microconcentrator (Amicon Corp., Danvers, MA). The 0.5kb Pst I fragment containing exon I was subcloned in both orientations into pBluescript (pBS; Stratagene Inc., La Jolla, CA). The hepatocyte promoter region and exon I were sequenced using the T7 primer binding site in pBS. Six primers used to sequence the remaining exons were: exon II, GGGTGTCAATCCCTGATCACT, AACCAGCCAGAC-AGCCAGCT, TTGCCAAGGAGAGTTCAAGA; exon III, CTG-CTACACTCTTCCAAACC; exon IV, GAAGAATGTGTGGGG-GCTGC; exon V, TCACATGCAGGCAGGGACCA. The regions sequenced are shown in Fig. 1 as solid bars. All sequencing was done with Sequenase (US Biochemical Corp. Cleveland, OH) using the dideoxy chain termination method. The sequence of the QOludwigshafen mutation was verified by amplifying and sequencing the opposite strand of exon II.
Verification ofthe mutation (a) Hybridization of the QOludwigshafen allele-specific oligonucleotide to polymerase chain reaction amplified DNA. Genomic DNA from the proband, and 10-100 pg of each control DNA, was amplified using Taq polymerase (24) as described (25) . QOludwigshafen control DNA was the cosmid clone used for sequencing. Normal control DNA was a clone containing exon II on a 6.5-kb Bam HI fragment, determined by sequencing to be normal in the region of the mutation (25) . Oligonucleotides specific for the QOludwigshafen mutation and its corresponding normal sequence ( Inc., Houston, TX). The analysis of PCR-amplified DNA was as described (25) except that for the QOludwigshafen probe, the hybridization temperature was 45°C and the final wash temperature in 5x SSPE was 50°C. DNA from 10 normal individuals was selected for testing based on previous haplotyping results ( 14) .
(b) Xho II digestion of PCR amplified exon II DNA. Genomic DNA from the proband, his daughter, a normal individual with the identical M2 haplotype, and individuals having a I AT deficiency variants Mmalton and Mduarte, were amplified by PCR and purified using a Centricon-30 (Amicon Corp.) microconcentrator. DNA was digested with Xho II according to manufacturer's specifications and the samples were visualized on a 2% agarose gel with ethidium bromide staining.
Hybridization ofother null alleles with allele-specific oligonucleotides
In order to fully characterize the 12 null alleles in our eight patients with rare deficiency alleles, particularly those that had identical haplotypes, leukocyte DNA was amplified from individuals with null alleles and haplotypes consistent with the QObellingham mutation, a previously sequenced QO allele (26) . The QObellingham control was a cosmid clone that had been demonstrated to contain the QObellingham mutation by allele-specific oligonucleotide (ASO) hybridization (Hofker, M. H., unpublished observation). The normal control was the cosmid clone used for sequencing the QOludwigshafen allele, determined to be normal in the region of the QObellingham mutation (this study). The hybridization temperature for the QObellingham probe was 55°C and the final temperature of the washes was 62°C in 5x SSPE.
Results
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Protein studies. The proband of PI type QOludZ had a serum a 1 AT concentration of 13% of normal, or 0. 17 mg/ml (normal concentration 1.32 mg/ml) (27) . When the serum of the proband, observed to be of PI type Z on isoelectric focusing, was examined by isoelectric focusing with immunoprinting, only Z a AT could be visualized. The presence of a null allele had originally been recognized through testing of his daughter, who was of PI type M1, with an a 1 AT concentration of 48% of d normal (0.63 mg/ml). Several years later, when taking oral contraceptives, her serum concentration of a 1 AT was 118% of normal (1.56 mg/ml). DNA haplotype analysis ofthe QOludwigshafen allele. The two different haplotypes found in the proband are shown in Table 1 . These haplotypes are associated with two alleles: Z, and a unique null allele, which we named QO*ludwigshafen according to nomenclature guidelines (28) . The QOludwigshafen mutation must have occurred in an M2 allele, as the QOludwigshafen allele ofaj-antitrvpsin 1879 z QOludt M RI T '7-1--associated haplotype is identical to the most common M2 haplotype for all enzymes tested. The same M2 haplotype is also associated with the Mmalton deficiency allele (25) . Cloning and sequencing. Six cosmid clones were purified; full-length genes were obtained in five as determined by digestion with Eco RI and hybridization with the probes 4.6 and 6.5. The absence ofthe polymorphic Msp I site in the intron 3' of exon I and the presence of the polymorphic Bst EII site in exon III ( Fig. 1 A) differentiated the QOludwigshafen clone from the Z clone.
Sequence was obtained for all five exons, all intron/exon junctions and the hepatocyte transcriptional control region (29) and compared with the genomic sequence of S (30) and cDNA of M2 (31). A single T to A base transversion in exon II was the only mutation found (Fig. 2) , except for the mutations characteristic of S and M2. The substitution results in an altered amino acid 92. The other differences observed were the absence of the S mutation (valine was found at amino acid 264) and the presence of the asparagine at 376 and histidine at 101 as in M2 (31).
Hybridization ofthe QOludwigshafen ASO to polymerase chain reaction amplified DNA. The QOludwigshafen mutation was confirmed by oligonucleotide hybridization after PCR amplification of both the cloned allele and genomic DNA from the proband (Fig. 3 ). Since the QOludwigshafen haplotype is identical to both the haplotype associated with the normal variant M2 and the Mmalton deficiency allele (25) , it was important to determine if the mutation was unique to the QOludwigshafen allele. Genomic DNA from six independent M2 haplotypes, other deficiency alleles having the same M2 haplotype, the proband, and his daughter were amplified along with the QOludwigshafen cosmid control and a subclone containing a normal exon II. The QOludwigshafen ASO hybridized to amplified genomic DNA from the proband and his daughter, confirming the inheritance of this null allele. Conversely, the QOludwigshafen ASO did not hybridize to the normal control, normal M2, Mmalton deficiency, or QOmattawa alleles. Mmalton cosmid clone determined to be normal in this region by sequencing (25) and the QOludwigshafen cosmid clone known to contain the mutation by sequence analysis. Amplified DNA from the proband and his daughter both showed, on agarose electrophoresis, fragments of 254 and 216 bp. This is consistent with their heterozygous state at the a lAT locus, QOludZ, and QOludM 1, respectively ( Fig. 4) . Examination ofother null alleles. In our eight patients with QO alleles we had identified five different haplotypes associated with a QO allele. Of the 12 QO alleles, seven had the Mlval213 haplotype associated with the QObellingham mutation (11), so we determined if all seven carried the QObellingham allele (data summarized in Table II ). This was done by hybridization with the QObellingham ASO after PCR amplification of genomic DNA (Fig. 5 ). Six of the seven alleles were QObellingham DNA samples from five normal individuals having haplotypes identical to that of QObellingham, and were amplified along with control clones containing exon III from either the QObellingham or the QOludwigshafen allele, the latter being normal in this region. The QObellingham ASO did not hybridize to any of the normal alleles, including those with an M lala2 13 haplotype or with M lval2 13 (the ancestral allele for M2), or to any of the deficiency alleles with haplotypes different from Ml val2 13. Based on haplotype analysis, we had previously suggested that the second QO allele found in 1880 G. Fraizer the proband in association with QOhongkong (32) might be a QObellingham allele (1 1), but this is not the case, as demonstrated by ASO hybridization. We have tentatively designated the different allele as QOhongkong2. Another potential QObellingham allele, found in combination with the deficiency allele Mmalton, was demonstrated to be a different null allele, which we designated QOcedarisland according to nomenclature guidelines (28) . ASO hybridization confirmed the presence of the QObellingham allele in four individuals, two of whom were homozygous for the QObellingham allele (data not shown) and two heterozygous for other deficiency alleles.
Discussion
The null alleles of a1 AT described to date, which have less than 1% of the normal concentration of a 1 AT, have base substitutions, deletions, or insertions that result in the generation ofa premature translational stop codon. However, other possible mechanisms for generating null alleles are promoter/en- dues always occur at this location (33) . However, the QOludwigshafen mutation replaces the nonpolar isoleucine with the polar asparagine. Examination of the three-dimensional model, based on studies of Loeberman et al. (34) , using both a computer image and a physical model of crystallized alAT, reveals that amino acid 92 lies in a hydrophobic pocket, along with methionine 63 and phenylalanine 82. The hydrophilic asparagine would result in a sharp twisting of the a-helix D, with resulting distortion of the tertiary structure. Although the disruption could result in impaired folding as occurs in Z a lAT, the complete absence of protein suggests the QOludwigshafen protein is destabilized. Normal mRNA is expected in this type of mutation. This type of mutation, which identifies critical regions for protein conformation, has been described for other null phenotypes such as found for Factor IX (35) , phenylalanine hydroxylase (36) , and hypoxanthine phosphoribosyltransferase (37) .
The QOludwigshafen haplotype is indistinguishable from that of one of the M2 haplotypes (I 1, 15), the background of the allele on which the mutation must have occurred. As predicted from haplotype data, the changes at amino acids 101 and 376 associated with M2 (31) are found in the QOludwigshafen sequence. To verify that the substitution in exon II ofthe QOludwigshafen allele is not characteristic of M2, which constitutes 10% of the normal M alleles, we hybridized the QOludwigshafen mutant oligonucleotide to PCR amplified DNA of the identical M2 haplotype. The QOludwigshafen allele was clearly distinguished from the M2 alleles and from the normal Ml or M3 alleles. Although direct sequencing of amplified exons can be carried out from genomic DNA, the prior cloning allows unambiguous assignment of the common mutations that occur in several exons. Since rare deficiency states will frequently occur in genetic compounds, correct matching ofexons will allow ambiguity from the direct genomic sequencing.
We have previously described a method for identifying null alleles based upon limited haplotype analysis (1 1), which can identify heterozygosity even in the absence of family studies. Haplotype analysis revealed heterozygosity in six of the eight individuals in our series who had null a 1 AT alleles. Two of these were heterozygous with PI*Z, two with PI*Mmalton, and two individuals were compound heterozygotes for different null alleles, as demonstrated by ASO hybridization. After determining the haplotype from which each null allele was derived, ASOs for those null alleles were hybridized to other null alleles with a similar haplotype background. Using this approach we have identified the likely presence of two new null alleles: QOhongkong2 and QOcedarisland. At least three deficiency mutations must have occurred on the same M2 haplotype background: Mmalton, QOludwigshafen, and QOcedarisland.
ASO hybridization verified the presence of QObellingham alleles in the homozygous state in one individual ofNorwegian and one of Dutch descent. The former individual had been provisionally identified as homozygous for the QOoslo allele (2) , which is therefore identical to QObellingham. QObellingham is apparently the most common of the null alleles found in individuals of European descent. Haplotype analysis is hampered when the individual being studied is of a different ethnic origin than that for which haplotype data are available, as for QOhongkong (i.e., hongkongl). By sequence analysis (32) , this allele must have been derived from an M2 haplotype, but the haplotype does not resemble the common M2 haplotype of European populations (15) . Our haplotype analysis for QOhongkongl was incomplete because phase could not be assigned to the one RFLP showing heterozygosity in this individual (4.6 probe and Ava II digestion). ASO hybridization allowed us to distinguish the new null allele (QOhongkong2), from the QObellingham allele in the compound heterozygote, despite haplotypes that differ at no more than one polymorphic restriction site. We have not used ASO hybridization for the QOgranite falls allele (38) because we have found this mutation results in the loss of a Mae II site in exon II ( 11) and none of the alleles we have examined have lost that site. Furthermore, the haplotype on which the QOgranite falls mutation occurred is the M 1ala2 13 haplotype, which is not present with any of the null alleles in our series.
Since the combined frequency for all the null alleles is estimated, based on unbiased ascertainment, to be 1.4 X 10-4 (8), the individual null alleles are even more rare. We have observed the QOludwigshafen allele in only one pedigree to date. This has been the case for all other null alleles described except for the QObellingham allele (26) which has been observed in several different pedigrees of European origin. Of four alleles ascertained without bias in Canadian caucasians, two were QObellingham, which is therefore estimated to have an allele frequency of 7 X 10-5.
Six QO alleles have now been sequenced (Table III) . QOcardiff(4 1) is not included, as the reported change of asparagine 256 to valine is the same as the mutation described for the PI*P allele (42) , coding for a somewhat unstable protein associated with 30% of the normal serum concentration of (26) and QOgranitefalls (43) are apparently associated with unstable transcripts, as no mRNA could be isolated from alveolar macrophages obtained from lung lavage, a normal source of a1AT mRNA. In contrast, the QOmattawa allele is associated with stable mRNA but no protein is secreted in in vitro expression assays (40) . The QOhongkong allele codes for a protein that is not transported from the rough endoplasmic reticulum to the Golgi apparatus but is apparently too unstable to form inclusions (32) . The null alleles lie at the extreme of a spectrum of alleles that result in various degrees of deficiency. Seven distinct deficiency alleles, which produce detectable plasma protein product, (-3-18% of normal) have also been sequenced and do not have premature termination codons as are found in the null alleles. Three of the four deficiency alleles associated with inclusion bodies have been sequenced. The PI Z mutation (glutamine to lysine at amino acid 342) (44, 45) and the Mmalton (25) and Mnichinin (46) mutations (deletion of phenylalanine at amino acid 51/52) result in proteins that readily aggregate in vitro and form stable inclusion bodies in the liver. The phenylalanine deletion of the latter two PI types occurred on different backgrounds, M2 and Ml val213, respectively. Similarly, the PI Z mutation has occurred on an M2 background in Ztunbridgewells (47) , which appears to be identical to PI*Zaugsberg (48) . Two of the deficiency alleles, Mheerlen (49) and Mprocida (50) , have amino acid substitutions involving a proline and therefore likely form unstable proteins. The Mheerlen substitution would change the bend of the i3-sheet B4; the Mprocida substitution would disrupt a-helix A. Neither are associated with liver inclusion bodies (50, 5 1). Mmineralsprings, which shows a modest reduction in concentration, is also functionally deficient (14% ofnormal) (52) . PI*Mduarte and PI* cobalt could be the same from protein studies but are not sequenced (1 1).
Clinical implications for lung destruction may be similar for all of the deficiency variants, except that there is evidence that even the low amount of a lAT produced in PI ZZ homozygotes is protective in comparison with PI QO homozygotes (53) . Liver disease has only been described in association with PI*Z (7) and PI*Mmalton (54) . Further studies of patients with rare deficiency alleles may eventually help clarify whether the plasma deficiency or liver accumulation of a1 AT is responsible for liver disease.
Haplotype and sequencing studies have now demonstrated a minimum of 15 different deficiency alleles, with different types of molecular defects. Characterization ofthe spectrum of mutations leading to a lAT deficiency allows delineation of amino acid residues critical for stability, for normal secretion, and for normal function.
